Effect of systemic infusion of esmolol on blood loss in patients undergoing posterior lumbar internal fixation (PLIF)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0005133

Enrollment

Registered

2020-06-16

Start date

2019-08-20

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : On the day of surgery, after entering the operating room of the patient, blood pressure, pulse, oxygen saturation, electrocardiogram, BIS (depth monitor of anesthesia using brain waves), end-ti

), remifentanil, and study medication. For Esmolol 1 Group, esmolol was continuously inused at a rate of 5 µg / kg / min, and for Esmolol 2 Group, esmolol was continuously infused at a rate of 10 µg /

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 19-80 years old patients undergoing posterior vertebral fixation (Level 2-3)

Exclusion criteria

Exclusion criteria: Patients who did not agree to participate in this study Patients with preoperative bradycardia (less than 50 pulses per minute) and arrhythmia Patients with cardiovascular diseases other than diabetes and high blood pressure (such as coronary artery disease, ischemic heart disease) Patients who are hypersensitive to esmolol

Design outcomes

Primary

Measure	Time frame
Intraoperative blood loss	—

Secondary

Measure	Time frame
Intraoperative cardiac output and cardiac index	—

Countries

Korea, Republic of

Contacts

Public ContactJin Joo

The Catholic University of Korea, Seoul St. Mary's Hospital

Outcome results